TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Kovanaze Vs. Articaine in Achieving Pulpal Anesthesia of Maxillary Teeth - Pediatric

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists Class I or II~* Preoperative heart rate of 55 to 100 beats per minute~* Maximum blood pressure reading of 166/100 mmHg~* Treatment for a pathology in the maxillary anterior tooth or premolar that requires administering local anesthesia~Additional Pediatric Inclusion Criteria:~* Children \>20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth~Additional Endodontic Inclusion Criteria:~* Adults (\>18 years) who require non-surgical root canal treatment in maxillary anterior teeth~Additional General Practice Inclusion Criteria:~* Adults who require restorations in the maxillary teeth that would need local anesthesia~Exclusion Criteria:~* Inadequately controlled thyroid disease~* Five or more nosebleeds in the past month~* Known allergy to any study drug or para-aminobenzoic acid~* History of methemoglobinemia~* Taking monoamine oxidase inhibitors, tricyclic antidepressants (i.e. amitriptyline), or non-selective beta adrenergic antagonists (i.e. propranolol);~* Taking oxymetazoline-containing products (i.e., Afrin) in the last 24 hours.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Kovanaze Nasal Spray (Pediatrics) (Type: EXPERIMENTAL): Children \>20 kg who require pulpotomy, restorative procedures, SS crowns in one maxillary tooth
- Articaine Injections (Pediatrics) (Type: ACTIVE_COMPARATOR): Children \>20 kg who require pulpotomy, restorative procedures, or stainless steel crowns in one maxillary tooth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients must be diagnosed with treatment-refractory neuroblastoma with no known curative treatment options. Tumor histology should be verified at diagnosis or relapse.~* Prior to enrollment, a determination of residual disease must be performed~* Patients must have a Lansky or Karnofsky performance scale score of ≥ 50%.~* Patients must have a life expectancy of ≥ 2 months (8 weeks).~* Total absolute neutrophil count (ANC) is at least 750, Hgb≥8 grams/dl, and plts ≥ 75K. PRBC transfusions are allowed.~* Patients with bone marrow disease will not evaluable for hematologic toxicity. These patients must have a peripheral absolute neutrophil count~  * 750, platelet count ≥ 50K and Hgb ≥8 grams/dl. Transfusions are permitted to meet both the platelet and hemoglobin criteria.~* Creatinine clearance or radioisotope GFR \> 70mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:~* ≤ 0.8 mg/dL (for patients 2 to 5 years of age)~* ≤ 1.0 mg/dL (for patients 6 to 9 years of age)~* ≤ 1.2 mg/dL (for patients 10 to 12 years of age)~* ≤ 1.4 mg/dL (for female patients ≥ 13 years of age)~* ≤ 1.5 mg/dL (for male patients 13 to 15 years of age)~* ≤ 1.6 mg/dL (for male patients ≥ 16 years of age)~* Total bilirubin ≤ 2.5 x upper limit of normal (ULN) for age, and~* SGPT (ALT) \< 2.5 x upper limit of normal (ULN) for age.~* SOS (sinusoidal obstruction syndrome, formerly known as veno-occlusive disease \[VOD\]), if present, should be stable or improving.~* Shortening fraction of \> 27% by echocardiogram, or ejection fraction of \> 55% by radionuclide angiography.~* No evidence of dyspnea at rest. If PFTs are performed, FEV1/FVC \> 60% by pulmonary function test.~* Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.~* CNS toxicity \< Grade 2.~Exclusion Criteria:~* Females of childbearing potential must have a negative pregnancy test.~* Patients of childbearing potential must agree to use an effective birth control method.~* Female patients who are lactating must agree to stop breast-feeding.~* All patients and/or their parents or legal guardians must sign a written informed consent.~* All institutional requirements for human studies must be met.~* Previous treatment with anti-GD2 and interleukin2 therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid and Interleukin-2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older presenting to the ED with acute syncope (defined as transient loss of consciousness) or near syncope (sensation of impending but not actual loss of consciousness) as a reason for ED visit.~Exclusion Criteria:~* persistent altered mental status~* alcohol or illicit drug-related loss of consciousness~* definite seizure, and transient loss of consciousness caused by head trauma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Immediate Ultrasound (Type: OTHER): A point-of-care ultrasound will be performed during the initial evaluation of the patient after randomization (Defined as Time 0)
- Delayed Ultrasound (Type: OTHER): A point-of-care ultrasound will be performed by the provider at 60 min after initial randomization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects will be included that are:~1. Currently admitted for treatment or observation at the investigational site at the time of enrollment;~2. In the weight range less than 5.0 kg (\<5.0 kg ) and more than 0.5 kg (\>0.5 kg );~3. Viable neonates (birth to 1 month of age) or infants (\>1 month to two years of age);~4. Able to safely undergo an MRI scan, as determined by the site's co-investigator neonatologist or medically qualified delegate;~5. Have parent(s), guardian(s), or legally authorized representative(s) willing and able to provide written informed consent for the subject's participation;~6. Are of appropriate size and shape to fit into the bore of the magnet, inclusive of all monitoring equipment, if any, necessary for the subject's routine clinical care:~   1. Maximum width (shoulder-to-shoulder measurement) less than eighteen (18 cm).~  2. Maximum length (head-to-foot measurement) less than sixty (60) cm. -~Exclusion Criteria:~* Subjects will be excluded that:~  1. Have parent(s), guardian(s), or legally authorized representative(s) that require that they accompany the subject into the MR environment that have contraindications to the MR environment or would otherwise be put at undue risk or discomfort, as determined by the investigators;~ 2. Require any non-removable medical devices that are not compatible with MR scanning (labeled as MR Unsafe, MR condition for which the scanning conditions are not met, or no MR safety labeling) that may pose hazards in the MR scanning or MR environment, in the opinion of the neonatologist co-investigator or medically qualified delegate;~ 3. Have other contraindications or could otherwise be expected to experience detrimental effects to safety, well-being, or medical care, as determined by the neonatologist co-investigator;~ 4. Require any scheduled standard of care procedures that are expected to be adversely impacted by participation in this study, in the opinion of the principal investigator, neonatologist co-investigator, or medically qualified delegate; and~ 5. Have been previously enrolled AND undergone any study procedures under the current study protocol (i.e. the same subject cannot undergo study procedures, including swaddling and/or MR scanning, more than once).

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Years
- Healthy Volunteers: f

Study Arms:
- 3.0 T Neonatal Scanner (Type: OTHER): All subjects who participate in this study will be scanned using the 3.0 T Neonatal MRI scanner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect on Nitrogen Retention of Two Different Posology Schemes of PKU GOLIKE PLUS 3-16 and Free AAs in Patients With Phenylketonuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed, informed consent obtained prior to being enrolled into the study and prior to starting any data collection. Consent of a legally authorized guardian is required for legally minor patients as defined by local regulation. If the patient is legally a minor, signed written consent shall be obtained from parent(s)/legal guardian and assent obtained from the patient, if applicable.~2. Male or female, aged 3-20 (limits included).~3. Patients with diagnosis of PKU at newborn screening.~4. Patients starting low Phe diet before 1 month of age.~5. Ability and willingness to comply with all study procedures and availability for the duration of the study.~Exclusion Criteria:~1. Known or suspected hypersensitivity to any excipients/components of the investigational products.~2. Treatment with therapy for PKU other than amino-acids supplementation.~3. Patients aged \>12 years old with 4 repeated average values of blood Phe \>600 µM in the previous 6 months.~4. Patients aged \<12 years old with 4 repeated average values of blood Phe \>360 µM in the previous 6 months.~5. Any moderate to severe medical condition, which in the opinion of the Investigator would interfere with the study procedures or study outcome (reasoning to be provided), such as history of clinically significant diseases or malfunctions including, but not limited to, gastrointestinal, renal, hepatic, pulmonary, cardiovascular or endocrine disease, hemophilia, hyperlipidemia, impaired glucose tolerance or diabetes (type 1 or 2), or anemia.~6. History of poor co-operation, non-compliance with medical treatments and diet, or poor adherence to investigational procedures.~7. Any current participation in another clinical trial involving investigational or marketed products in the 3 months prior to the inclusion in this study.~8. Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- A. One day treatment with 3 self-administrations of GOLIKE PLUS 3-16 (Type: ACTIVE_COMPARATOR): None
- B. One day treatment with 2 self-administrations of GOLIKE PLUS 3-16 (Type: ACTIVE_COMPARATOR): None
- C. One day treatment with 3 self-administrations of free AAs (Type: PLACEBO_COMPARATOR): None
- D. One day treatment with 2 self-administrations of free AAs (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Pain After Video-assisted Thoracoscopic Surgery (VATS) Surgery for Pneumothorax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PSP~* Able to understand and give consent~* Can read~* Residing in Denmark~Exclusion Criteria:~* Unable to understand the written information in Danish~* Abuse (Medicine, Drugs, Alcohol)~* Severe psychiatric Illness~* Conflicting neurological disease~* Conversion to open surgery~* Use of neuroaxial analgesia~* Use of electric cauterizer necessitated~* Additional thoracic surgery in the investigation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- 5 mm equipment (Type: EXPERIMENTAL): 5 mm videoscopic equipment
- 10 mm (Type: EXPERIMENTAL): Use of standard 10 mm VATS equipment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Improving Medication Adherence in ADHD Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ADHD; currently prescribed an FDA-approved medication for ADHD, history of medication nonadherence (taking less than 60% of prescribed doses); full scale Intelligence Quotient \>80, no current language delay and/or had no language delays before age 3.~Exclusion Criteria:~* active medical conditions that could be worsened by stimulants (seizures, arrhythmias, hypertension) unless patient has clearance from primary specialist taking care of existing condition, pregnancy, Bipolar Disorder, schizophrenia, and/or other psychotic disorders, and diagnosis of current substance abuse or dependence (except nicotine), current psychotropic medication for conditions other than ADHD.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Medication as usual (Type: ACTIVE_COMPARATOR): Medication as typically prescribed by physician.
- Medication as usual + STAR (Type: ACTIVE_COMPARATOR): Medication as typically prescribed with the addition of the psychosocial intervention to improve medication adherence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed liver metastases secondary to uveal melanoma~  * Surgically incurable or unresectable disease~* No detectable extrahepatic metastases~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count ≥ 2,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~Hepatic~* Bilirubin \< 1.5 times upper limit of normal (ULN)~* ALT and AST \< 5 times ULN~* Alkaline phosphatase \< 5 times ULN~* Gamma-glutamyltransferase \< 5 times ULN~* Lactic dehydrogenase \< 5 times ULN~Renal~* BUN \< 1.5 times ULN~* Creatinine ≤ 1.5 times ULN~Cardiovascular~* No uncontrolled angina pectoris~* No myocardial infarction within the past 6 months~* No uncontrolled high blood pressure~* No evolutive intracranial hypertension~* No other severe cardiac disease~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No active gastroduodenal ulcer~* No diabetes~* No active or uncontrolled infection~* No psychological, familial, sociological, or geographical condition that would preclude study compliance and follow-up~* No other uncontrolled severe medical condition~* No other malignancy within the past 5 years except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent immunologic or biologic therapy~Chemotherapy~* No other concurrent chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy for metastatic disease~* No concurrent radiotherapy~Surgery~* Recovered from prior major surgery~Other~* No prior antineoplastic drugs for metastatic disease~* More than 4 weeks since prior investigational drugs~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Goal Directed Hemodynamic Management and Renal Outcome After Renal Transplant Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Renal Transplant Surgery~* Age ≥ 65 years~* Written informed consent~Exclusion Criteria:~* Contraindications for an arterial line in the femoral artery:~  * stents~ * bypasses~ * severe peripheral artery occlusive disease

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- P group (Type: None): Group P: Fluid Management according to measurements with PiCCO®
- C group (Type: None): Group C: Conventional fluid management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have had an episode of symptomatic Transient ischemic attack (TIA) or episode of ischemic stroke.~  * Ischemic stroke is defined as an episode of transient or neurological dysfunction caused by focal brain or retinal ischemia with recent infarction on imaging~ * A TIA is defined as transient episode of neurologic dysfunction typically lasting less than one hour caused by focal brain or retinal ischemia without recent infarction on imaging.~Exclusion Criteria:~* Known etiology of TIA or ischemic stroke~* TIA or stroke caused by spinal ischemia~* TIA only presenting with non-localising symptoms~* Uncertainty about the diagnosis of TIA because of unclear clinical symptoms~* Myocardial infarction \<6 months before stroke~* Coronary Artery Bypass Grafting \<6 months before stroke~* Severe valvular heart disease~* Documented history of atrial fibrillation or atrial flutter~* Permanent indication for oral anticoagulation at enrolment~* Patient has permanent OAC contraindication~* Patient is included in another randomized trial~* Left ventricular aneurysm on echocardiography~* Thrombus on echocardiographyRenal dysfunction (creatinine clearance \<30 mL/min/1.73m2)~* Patient has life expectancy of \<1 year~* Patient is not willing to sign the informed consent form~* Patient is \<18 years of age~* Patient is considered an incapacitated adult~* Patient is not in possession of a smartphone with Android Operating System (OS) or iOS.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 7-Day Holter monitor (Type: ACTIVE_COMPARATOR): This arm will receive a 7-Day Holter monitor directly after randomization.
- Single lead ECG device (Type: EXPERIMENTAL): This arm will be asked to take a single lead ECG two times per day and in case of complaints with a single lead ECG device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Endoscope-assisted, Minimally-invasive Cortical Access System for Chronic Subdural Evacuation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 55 years of age or greater.~* Have a clinically symptomatic chronic subdural hematoma greater than 1 cm in maximal thickness and be judged clinically to need subdural evacuation.~Exclusion Criteria:~* Failure to obtain consent.~* Vulnerable study population.~* Any need for chronic anticoagulation.~* Pregnancy (verified by pregnancy testing at screening or medical history of a hysterectomy, oophorectomy, or post-menopausal).Prior surgery for subdural hematoma.~* Glasgow Coma Scale (GCS) less than 8.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (Type: EXPERIMENTAL): During clinically indicated surgery for subdural hematoma, the patient will undergo a single burr hole evacuation with the MICAS device with endoscopic assistance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy